Alterity Therapeutics (ASX:ATH) Institutional Ownership: 10.14% (As of Jul. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ATH Alterity Therapeutics Ltd ASX:ATH
31 GF Score
Price A$0.64
View Full Analysis

What is Alterity Therapeutics Institutional Ownership?

Alterity Therapeutics ASX:ATH 31 Institutional Ownership is 10.14% as of Jul. 13, 2026. GuruFocus rates ASX:ATH with a GF Score™ of 31/100.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Alterity Therapeutics's institutional ownership is 10.14%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Alterity Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Alterity Therapeutics's Float Percentage Of Total Shares Outstanding is 98.01%.

Alterity Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Institutional Ownership Chart

Alterity Therapeutics Historical Data

The historical data trend for Alterity Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 5.48 4.84 4.84 4.99 4.99 4.96 4.96 4.96 4.90 10.14
ASX:ATH
31GF Score
Alterity Therapeutics Ltd ASX:ATH
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 10.14% mean?
Alterity Therapeutics (ASX:ATH) has a Institutional Ownership of 10.14% as of Jul. 13, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Alterity Therapeutics and its competitors.
Is Alterity Therapeutics' Institutional Ownership too high?
Alterity Therapeutics' current Institutional Ownership is 10.14%. Overall, Alterity Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Institutional Ownership compare to VRTX and REGN?
Alterity Therapeutics' Institutional Ownership of 10.14% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Alterity Therapeutics and its competitors. Alterity Therapeutics's current Institutional Ownership is 10.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (ASX:ATH) has a current Institutional Ownership of 10.14%. The current Institutional Ownership is 10.14%. Alterity Therapeutics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Alterity Therapeutics (ASX:ATH), the current Institutional Ownership is 10.14% as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
31GF Score

Get the complete analysis for ASX:ATH

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.64
Price